Abstract
Skeletal muscle injury is a common and debilitating orthopaedic condition. Unfortunately, current treatment protocols inadequately facilitate full muscular recovery. New research is investigating modalities that regulate postinjury muscle fibrosis or scar tissue, which in excess can increase muscle stiffness and risk of reinjury. Losartan, a well-known angiotensin II receptor blocker, reduces muscle fibrosis after acute muscle injury in animal models by indirectly inhibiting transforming growth factor-β1, a profibrotic growth factor released during muscle healing. Although promising results have been shown thus far, additional human clinical trials are needed to confirm these findings and provide guidance on treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JBJS Journal of Orthopaedics for Physician Assistants
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
